This company listing is no longer active
Acorda Therapeutics Past Earnings Performance
Past criteria checks 0/6
Acorda Therapeutics has been growing earnings at an average annual rate of 10.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 36.5% per year.
Key information
10.3%
Earnings growth rate
20.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -36.5% |
| Return on equity | -30.8% |
| Net Margin | -17.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Acorda Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 117 | -21 | 93 | 0 |
| 31 Mar 23 | 118 | -58 | 102 | 0 |
| 31 Dec 22 | 119 | -66 | 106 | 0 |
| 30 Sep 22 | 124 | -106 | 103 | 0 |
| 30 Jun 22 | 122 | -119 | 110 | 0 |
| 31 Mar 22 | 123 | -95 | 112 | 0 |
| 31 Dec 21 | 129 | -104 | 119 | 0 |
| 30 Sep 21 | 130 | -166 | 129 | 0 |
| 30 Jun 21 | 152 | -132 | 139 | 0 |
| 31 Mar 21 | 154 | -127 | 145 | 0 |
| 31 Dec 20 | 153 | -100 | 153 | 0 |
| 30 Sep 20 | 165 | 49 | 158 | 0 |
| 30 Jun 20 | 160 | -222 | 167 | -35 |
| 31 Mar 20 | 176 | -232 | 178 | -16 |
| 31 Dec 19 | 192 | -273 | 190 | 0 |
| 30 Sep 19 | 211 | -329 | 188 | 26 |
| 30 Jun 19 | 306 | -79 | 183 | 84 |
| 31 Mar 19 | 409 | -6 | 177 | 91 |
| 31 Dec 18 | 471 | 34 | 172 | 105 |
| 30 Sep 18 | 591 | -147 | 172 | 109 |
| 30 Jun 18 | 589 | -158 | 169 | 119 |
| 31 Mar 18 | 575 | -213 | 174 | 145 |
| 31 Dec 17 | 588 | -223 | 180 | 161 |
| 30 Sep 17 | 541 | -55 | 184 | 185 |
| 30 Jun 17 | 535 | -43 | 198 | 206 |
| 31 Mar 17 | 523 | -53 | 211 | 205 |
| 31 Dec 16 | 520 | -35 | 218 | 203 |
| 30 Sep 16 | 510 | -22 | 229 | 194 |
| 30 Jun 16 | 522 | -6 | 226 | 182 |
| 31 Mar 16 | 509 | 14 | 216 | 163 |
| 31 Dec 15 | 493 | 11 | 205 | 149 |
| 30 Sep 15 | 480 | 2 | 202 | 131 |
| 30 Jun 15 | 437 | 10 | 199 | 104 |
| 31 Mar 15 | 421 | 14 | 196 | 90 |
| 31 Dec 14 | 401 | 18 | 202 | 73 |
| 30 Sep 14 | 376 | 24 | 191 | 62 |
| 30 Jun 14 | 355 | 19 | 186 | 59 |
| 31 Mar 14 | 345 | 18 | 183 | 56 |
| 31 Dec 13 | 336 | 16 | 185 | 54 |
| 30 Sep 13 | 325 | 143 | 183 | 58 |
| 30 Jun 13 | 318 | 145 | 181 | 56 |
| 31 Mar 13 | 306 | 146 | 177 | 55 |
| 31 Dec 12 | 306 | 155 | 169 | 54 |
| 30 Sep 12 | 297 | 35 | 159 | 46 |
Quality Earnings: CDG is currently unprofitable.
Growing Profit Margin: CDG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CDG is unprofitable, but has reduced losses over the past 5 years at a rate of 10.3% per year.
Accelerating Growth: Unable to compare CDG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: CDG has a negative Return on Equity (-30.82%), as it is currently unprofitable.